| Fluoropyrimidines (e.g. 5-fluorouracil, capecitabine, gemcitabine) |
Coronary vasospasm, thrombosis, endothelial injury |
| Vascular endothelial growth factor inhibitors (e.g. bevacizumab) |
Endothelial dysfunction, coronary vasospasm, vascular remodelling, inflammation, platelet activation, increased plaque vulnerability |
| Alkylating agents (e.g. cisplatin) |
Pro-coagulant state, coronary thrombosis (endothelial damage, thromboxane production, platelet activation and aggregation) |
| Immunomodulatory agents (e.g. lenalidomide, pomalidomide) |
Arterial thrombosis |
| Hormone therapy (e.g. abiraterone) |
Accelerated atherosclerosis |
| Anti-microtubule agents (e.g. paclitaxel, docetaxel) |
Coronary vasospasm |
| Vinca alkaloids (e.g. vincristine, vinblastine) |
Coronary vasospasm |
| Tyrosine kinase inhibitors (e.g. niolotinib and ponatinib) |
Endothelial dysfunction, prothrombotic state, increased plaque vulnerability |
| Radiotherapy (e.g. mantle radiotherapy) |
Endothelial injury, plaque rupture, thrombosis, fibrosis of the vessel wall, accelerated atherosclerosis |
